Transient elastography: should XL probe be used in all overweight patients?

References

• Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–689.
   PubMed Web of Science ®Google Scholar
• Tremmel M, Gerdtham UG, Nilsson PM, et al. Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health. 2017;14:435.
   PubMed Web of Science ®Google Scholar
• Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. Targets Ther. 2014;7:587–591.
   PubMedGoogle Scholar
• Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679–689.
   PubMed Web of Science ®Google Scholar
• Kachur S, Lavie CJ, de Schutter A, et al. Obesity and cardiovascular diseases. Minerva Med. 2017;108:212–228.
   PubMed Web of Science ®Google Scholar
• Sasaki A, Nitta H, Otsuka K. Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. Front Endocrinol. 2014;5:164.
   PubMed Web of Science ®Google Scholar
• Subichin M, Clanton J, Makuszewski M, et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11:137–141.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9:65–90.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123–133.
   PubMed Web of Science ®Google Scholar
• Masugi Y, Abe T, Tsujikawa H, et al. Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatol Commun. 2018;2:58–68.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e10.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49:1017–1044.
   PubMed Web of Science ®Google Scholar
• Lim JK, Flamm SL, Singh S, et al. Clinical guidelines committee of the American gastroenterological A. American Gastroenterological Association Institute guideline on the role of elastography in the evaluation of liver fibrosis. Gastroenterology. 2017;152:1536–1543.
   PubMed Web of Science ®Google Scholar
• Liu K, Wong VW, Lau K, et al. Prognostic value of controlled attenuation parameter by transient elastography. Am J Gastroenterol. 2017;112:1812–1823.
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Orlic L, Franjic N, et al. Transient elastography (FibroScan((R))) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease – where do we stand?. World J Gastroenterol. 2016;22:7236–7251.
   PubMed Web of Science ®Google Scholar
• Myers RP, Pollett A, Kirsch R, et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910.
   PubMed Web of Science ®Google Scholar
• Caussy C, Chen J, Alquiraish MH, et al. Association between obesity and discordance in fibrosis stage determination by magnetic resonance vs transient elastography in patients with nonalcoholic liver disease. Clin Gastroenterol Hepatol. 2018;16:1974.
   PubMed Web of Science ®Google Scholar
• Pang JX, Pradhan F, Zimmer S, et al. The feasibility and reliability of transient elastography using Fibroscan(R): a practice audit of 2335 examinations. Can J Gastroenterol Hepatol. 2014;28:143–149.
   PubMed Web of Science ®Google Scholar
• Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–835.
   PubMed Web of Science ®Google Scholar
• Foucher J, Castera L, Bernard PH, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2006;18:411–412.
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Vergniol J, Foucher J, et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30:1043–1048.
   PubMed Web of Science ®Google Scholar
• Friedrich-Rust M, Hadji-Hosseini H, Kriener S, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010;20:2390–2396.
   PubMed Web of Science ®Google Scholar
• Lemoine M, Shimakawa Y, Njie R, et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia. Aliment Pharmacol Ther. 2014;39:188–196.
   PubMed Web of Science ®Google Scholar
• Mederacke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 2009;29:1500–1506.
   PubMed Web of Science ®Google Scholar
• Carrion JA, Puigvehi M, Coll S, et al. Applicability and accuracy improvement of transient elastography using the M and XL probes by experienced operators. J Viral Hepat. 2015;22:297–306.
   PubMed Web of Science ®Google Scholar
• Myers RP, Pomier-Layrargues G, Kirsch R, et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J Hepatol. 2012;56:564–570.
   PubMed Web of Science ®Google Scholar
• Wong GL, Vergniol J, Lo P, et al. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan(R)): applying the cut-offs of M probe to XL probe. Ann Hepatol. 2013;12:402–480.
   Web of Science ®Google Scholar
• Garg H, Aggarwal S, Shalimar, et al. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg Obes Relat Dis. 2018;14:81–91.
   PubMed Web of Science ®Google Scholar
• Harris RC, Delahooke T, Aithal GP, et al. The XL probe: a luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. UEG J. 2018;6(9):1372–1379.
   Google Scholar
• Puigvehi M, Broquetas T, Coll S, et al. Impact of anthropometric features on the applicability and accuracy of FibroScan((R)) (M and XL) in overweight/obese patients. J Gastroenterol Hepatol. 2017;32:1746–1753.
   PubMed Web of Science ®Google Scholar
• Durango E, Dietrich C, Seitz HK, et al. Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients. Hepat Med. 2013;5:43–52.
   PubMedGoogle Scholar
• Sporea I, Șirli R, Mare R, et al. Feasibility of transient elastography with M and XL probes in real life. Med Ultrason. 2016;18:7–10.
   PubMed Web of Science ®Google Scholar
• Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.
   PubMed Web of Science ®Google Scholar
• Chan WN, Mahadeva S, Wong VW, et al. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? J Gastroenterol Hepatol. 2018;33(10):1787–1794.
   PubMed Web of Science ®Google Scholar
• de Ledinghen V, Hiriart JB, Vergniol J, et al. Controlled attenuation parameter (CAP) with the XL probe of the Fibroscan((R)): a comparative study with the M probe and liver biopsy. Dig Dis Sci. 2017;62:2569–2577.
   PubMed Web of Science ®Google Scholar